AIN457 150 mg: Clinical Trials

4 trials of AIN457 150 mg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4

Follow AIN457 150 mg: new trials by email Literature Review of AIN457 150 mg trials Research Report on AIN457 150 mg

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg - Ankylosing Spondylitis
Phase 3CompletedNovartis Pharmaceuticals8592017-11-302023-08-21
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
secukinumab 150 mg, secukinumab 300 mg, Placebo - Moderate to Severe Palmoplantar Psoriasis
Phase 3CompletedNovartis Pharmaceuticals2052013-06-192018-02-22
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Secukinumab (75 mg), Placebo, Secukinumab (150 mg) - Anklyosing Spondylitis
Phase 3CompletedNovartis Pharmaceuticals2192012-10-182019-10-30
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
AIN457 150 mg, AIN457 300 mg, Placebo - Moderate to Severe Chronic Plaque-Type Psoriasis
Phase 3CompletedNovartis Pharmaceuticals6752012-09-162018-05-25

Conditions studied

Plaque, Amyloid (2)  ·  Spondylitis, Ankylosing (2)  ·  Dermatitis (1)  ·  Pruritus (1)  ·  Psoriasis (1)  ·  Skin Diseases (1)

Sponsors

Novartis Pharmaceuticals (4)

Countries

Canada (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Czechia (3)  ·  Finland (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Russia (3)  ·  Slovakia (3)  ·  Spain (3)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  France (2)  ·  Israel (2)

Results publications

PMID 26699169, PMID 27582421, PMID 28235249, PMID 28544533, PMID 28580579, PMID 30564451, PMID 31203228, PMID 31983056, PMID 32352653, PMID 33227175, PMID 33252266, PMID 33351179, PMID 33722947, PMID 33978600, PMID 34618347, PMID 34773130, PMID 38273597, PMID 41965705